hyperphosphatemia
Conditions
Interventions
Single dose group:Oral JMKX003002 tablets or placebo
Multiple dose group:Oral medication 7 days
Sponsors
Huashan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. No gender limmit, subjects aged 18-45 years (including boundary values); 2. After comprehensive physical examination (vital signs, physical examination), laboratory examination (blood routine, blood biochemistry, urine routine, coagulation routine), 12-lead electrocardiogram and other examinations, it was determined that there was no abnormality or abnormality had no clinical significance; 3. Understand the research procedures and methods, voluntarily participate in this experiment, comply with the relevant instructions of the study, and sign the informed consent in person.
Exclusion criteria
Exclusion criteria: 1. There is evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, liver, neuropsychiatric disorders, or any condition that the investigator has determined may affect drug absorption, distribution, metabolism, or excretion; 2. Have a history of malignant tumors or currently have malignant tumors; 3. Other conditions in which subjects are deemed unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematology;Chemistry;Coagulation function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics; | — |
Countries
China
Contacts
Public ContactZhang Jing, Xue Jun
Huashan Hospital Fudan University
Outcome results
None listed